Tag Archives: business

The future of GDPR? Focus on Automated Decisions

The Digital Omnibus Proposal.  The so called “Digital Omnibus” regulation proposal promises to lighten the burden of compliance with data protection legislation. Its aim is “to ensure that the rules continue to be fit for supporting innovation and growth”. Europe is not giving up on privacy, but it is willing to simplify it.

EDPB and EDPS Chime In.  The proposal, published in November 2025, has recently been the subject matter of a joint opinion by the European Data Protection Board and the European Data Protection Supervisor. While these two bodies are apparently in favor of facilitating GDPR compliance and strengthening consistency in its application, they express significant concerns regarding the impact of the changes on the fundamental rights and freedoms of individuals. They also fear that the proposal will create additional legal uncertainties.

The GDPR of the Future.  Gitti and Partners is embarking in a series of blog posts to explain what the GDPR may look like if the Digital Omnibus proposal becomes law. Today we focus on changes to the provision on automated decisions.

Automated Decisions: from Right to Prohibition.  Article 22 of the current GDPR regulates automated individual decision-making. The current language of the provision frames the rule as a “right”: a data subject is entitled not to be subject to a decision based solely on automated processing, unless certain conditions apply. The new proposal, instead, shapes a similar rule as a prohibition.

Conditions for Automated Decisions.  The new proposal reads (new language highlighted in yellow): “1. A decision which produces legal effects for a data subject or similarly significantly affects him or her may be based solely on automated processing, including profiling, only where that decision: (a) is necessary for entering into, or performance of, a contract between the data subject and a data controller regardless of whether the decision could be taken otherwise than by solely automated means. […]”

While – as before – the automated decision is legitimate if necessary to enter into or perform a contract with the data subject, the novelty is that the necessity of the automated decision can be assessed “regardless of whether the decision could be taken otherwise than by solely automated means”. Therefore:

  • An automated decision that does not produce any legal effects is fine.
  • An automated decision producing legal effects may be based on automated processing only if the decision is necessary to enter into or perform a contract with the data subject.
  • No automated decision is allowed unless it is necessary to enter or perform a contract with the data subject.
  • In order to add certainty to the interpretation of the requirement of “necessity”, the proposal clarifies that the decision may be regarded as necessary also if the decision could be made by a human. In the words of the EDPB/EDPS opinion, “the requirement of necessity does not mean that the mere fact that a decision could theoretically also be taken by a human should prevent the controller from taking the decision by solely automated means”.
  • In short, “The fact that the decision could also be taken by a human does not prevent the controller from taking the decision by solely automated processing” (recital (38) of the Digital Omnibus proposal).

Bottom line: the data controller may choose a human decision process or an automated decision process so long as they are necessary to enter into or perform a contract with the data subject.

In conclusion, as shown in the “AI First” policy, the EU is now worried that AI may not be fully exploited. The above changes are supposed to encourage automated decisions even if such decisions could be taken by a human being.

Stay tuned for more angles of the Digital Omnibus.

Therapeutic cannabis in Italy: business opportunities

Italy’s only authorized medical cannabis facility is currently controlled by the military. However, the production site, located in the Florence area, cannot keep up with the increasing demand, creating shortages for patients and barriers to its prescription by physicians (whose patients are unlikely to be able to obtain the quantities needed).

As Colonel Modica of the Italian Military recognizedThe health ministry and the defense ministry are trying to fix the shortfall because there’s been a huge increase in cannabis prescriptions and the number of patients who need them”.

Meanwhile, pressed by the patients’ associations, the Italian Health Care Ministry Giulia Grillo announced not only the increase of import of therapeutic cannabis products from the Netherlands (to cover the short-term shortages), but also the start of a longer-term project, eventually leading to the creation of a public-private partnership for the production of cannabis. “An invitation to present expressions of interest will be published in order to increase the production of therapeutic cannabis“, Ministry said. Although underlining that an appropriate time frame will be needed in order to implement the project, the Ministry confirmed that the cannabis production activity is “of great interest for both the Defense and the Public Health Care” and crucial in order to satisfy the increasing needs of both domestic and foreign markets.

The increase in the domestic production of therapeutic cannabis, along with the overall demand for it, appears to be inevitable.

On the other hand, the boom of “light cannabis” products in Italy (i.e., containing THC in a percentage lower than 0.2 and, therefore, expressly declared legal in Italy starting from January 2017) seems to have encountered some obstacles lately.

The Advisory Board of the Italian Health Care Ministry (Consiglio Superiore di Sanità) issued a report last spring, recommending the adoption of measures aimed at prohibiting the sale of light cannabis products.

In addition to that, an internal note of the Ministry of Home Affairs, recently made public, promoted a zero-tolerance approach and a strict application of the relevant laws and regulations. Such steps have caused great uncertainty and concerns amongst those who have invested in what came to the media’s attention in 2017 as a State-backed business.

Hence, the latest developments relating to therapeutic cannabis in Italy indicate that new business opportunities for both exporters and producers of cannabis-based prescriptions are likely to be offered in the Italian market. Conversely, serious questions can be raised in connection to the light-cannabis boom, in view of the inconsistent approach recently taken by Italian authorities.